CNS Pharmaceuticals, Inc.

Listed Company

CNSPCIK 0001729427NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsNevadaFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-15.85M

Total Assets

—

Equity

—

Shares Out

1.46M

Op. Cash Flow

$-13.81M

Business

CNS Pharmaceuticals, Inc. is a clinical pharmaceutical company focused on developing anti-cancer drug candidates for brain and central nervous system tumors. It develops TPI 287, a brain-penetrant abeotaxane taxane derivative, and Berubicin, an anthracycline designed to cross the blood-brain barrier, and seeks additional CNS oncology compounds. Key business activities comprise clinical development, licensing and intellectual property management, with manufacturing contracted to third parties and no internal sales organization. Programs are pursued under exclusive licenses covering the U.S., Canada, Mexico and Japan and via multicenter clinical trial networks and potential commercial partners.

Summary from filing dated 2025-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
General and administrative	6	6	5	6	5
Research and development	10	9	14	9	10
Total operating expenses	16	15	19	15	14
Loss from operations	−16	−15	−19	−15	−14
Other expense	−2,560	0	—	—	—
Interest income	153,785	60,262	27,687	—	—
Interest expense	−15,230	−16,120	−13,805	—	—
Total other income (expense)	135,995	44,142	13,882	−7,027	−9,285
Net loss	−16	−15	−19	−15	−14
Loss per share - basic	−35.75	−466.89	−12,509	−11.22	−16.5
Loss per share - diluted	−35.75	−466.89	−12,509	−11.22	−16.5
Weighted average shares outstanding - basic	443,369	31,823	1,507	1	878,443
Weighted average shares outstanding - diluted	443,369	31,823	1,507	1	878,443

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	7	6	548,721	10	5
Deferred offering costs	45,486	20,637	202,859	0	334,138
Subscription receivable	0	882,539	0	—	—
Prepaid expenses and other current assets	856,301	1	839,590	3	2
Total current assets	8	9	2	13	7
Prepaid expenses, net of current portion	502,962	36,430	104,750	482,806	929,688
Property and equipment, net	17,703	6,005	4,933	5,664	16,109
Total noncurrent assets	520,665	42,435	109,683	488,470	1
Total Assets	9	9	2	13	9
Accounts payable and accrued expenses	4	2	6	5	—
Notes payable	328,571	326,072	300,806	409,968	387,794
Total current liabilities	4	3	6	5	3
Total Liabilities	4	3	6	5	3
Commitments and contingencies	—	—	—	—	—
Preferred stock, $0.001 par value, 5,000,000 shares authorized and 0 shares issued and outstanding	0	0	0	0	0
Common stock, $0.001 par value, 300,000,000 shares authorized and 632,516 and 117,796 shares issued and outstanding, respectively	633	118	2	1,617	949
Additional paid-in capital	105	91	65	59	42
Accumulated deficit	−100	−84	−70	−51	−35
Total Stockholders' Equity (Deficit)	5	6	−4	8	6
Total Liabilities and Stockholders' Equity (Deficit)	9	9	2	13	9

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation	187,728	838,957	1	1	2
Depreciation	3,918	3,306	4,134	11,756	13,070
Common stock issued for license agreement	0	596,303	—	—	—
Loss (gain) on disposal of fixed assets	2,559	−190	498	3,111	0
Prepaid expenses and other current assets	302,799	−59,972	2	860,451	—
Accounts payable and accrued expenses	2	−4	1	2	—
Net cash used in operating activities	−14	−17	−14	−11	−14
Purchase of property and equipment	−18,175	−4,188	−3,901	−4,422	−5,748
Net cash used in investing activities	−18,175	−4,188	−3,901	−4,422	−5,748
Payments of deferred offering costs	−64,082	−66,750	−202,859	0	—
Payments on notes payable	−297,553	−300,806	−438,733	−427,700	−477,490
Stock repurchased during stock split rounding	−2,043	0	—	—	—
Proceeds from subscription receivable	882,539	0	—	—	—
Proceeds from exercise of warrants	3,627	21,325	3	2,734	332,750
Proceeds from sale of common stock	14	23	2	16	5
Net cash provided by financing activities	15	23	5	16	5
Net change in cash and cash equivalents	739,636	6	−10	5	−9
Cash paid for interest	15,267	13,599	13,805	8,094	9,774
Cash paid for income taxes	0	0	0	0	0
Prepaid expense financed with note payable	360,197	326,072	329,571	449,874	—
Reclassification of deferred offering costs to equity	39,233	248,972	0	—	—
Common stock issued for subscription receivable	0	882,539	0	—	—
Stock issued for stock split rounding	0	2	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro